{
  "denotations": [
    {
      "id": "T1",
      "obj": "Gene_or_protein",
      "span": {
        "begin": 18,
        "end": 50
      }
    },
    {
      "id": "T2",
      "obj": "Gene_or_protein",
      "span": {
        "begin": 53,
        "end": 57
      }
    },
    {
      "id": "T4",
      "obj": "Disease",
      "span": {
        "begin": 255,
        "end": 281
      }
    },
    {
      "id": "T5",
      "obj": "Disease",
      "span": {
        "begin": 284,
        "end": 289
      }
    },
    {
      "id": "T6",
      "obj": "Chemical",
      "span": {
        "begin": 105,
        "end": 168
      }
    },
    {
      "id": "T7",
      "obj": "Gene_or_protein",
      "span": {
        "begin": 141,
        "end": 143
      }
    },
    {
      "id": "T8",
      "obj": "Gene_or_protein",
      "span": {
        "begin": 123,
        "end": 138
      }
    },
    {
      "id": "T9",
      "obj": "Chemical",
      "span": {
        "begin": 65,
        "end": 86
      }
    }
  ],
  "sourcedb": "PubMed",
  "sourceid": "15638955_4",
  "text": "Inhibition of the epidermal growth factor receptor ( EGFR ) with monoclonal antibodies or small-molecule inhibitors of the tyrosine kinase ( TK ) domain of the receptor have demonstrated modest , albeit significant , antitumor activities in patients with non-small-cell lung cancer ( NSCLC ) ."
}
